share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Kewalramani Reshma

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Kewalramani Reshma

福泰製藥 | 4:持股變動聲明-高管 Kewalramani Reshma
美股sec公告 ·  05/22 16:26
Moomoo AI 已提取核心訊息
Vertex Pharmaceuticals CEO & President, Kewalramani Reshma, completed a sale of 15,202 shares of common stock on May 20, 2024. The transaction was executed at a price of $447.00 per share, resulting in a total sale value of $6,795,294. Following the sale, Reshma's direct holdings in the company amount to 121,374 shares. The sale took place in an open market transaction, as reported by Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals CEO & President, Kewalramani Reshma, completed a sale of 15,202 shares of common stock on May 20, 2024. The transaction was executed at a price of $447.00 per share, resulting in a total sale value of $6,795,294. Following the sale, Reshma's direct holdings in the company amount to 121,374 shares. The sale took place in an open market transaction, as reported by Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals首席執行官兼總裁Kewalramani Reshma於2024年5月20日完成了15,202股普通股的出售。該交易以每股447.00美元的價格執行,總銷售價值爲6,795,294美元。出售後,雷什瑪在該公司的直接持股量爲121,374股。據Vertex Pharmicals Inc.報道,此次出售是在公開市場交易中進行的。
Vertex Pharmaceuticals首席執行官兼總裁Kewalramani Reshma於2024年5月20日完成了15,202股普通股的出售。該交易以每股447.00美元的價格執行,總銷售價值爲6,795,294美元。出售後,雷什瑪在該公司的直接持股量爲121,374股。據Vertex Pharmicals Inc.報道,此次出售是在公開市場交易中進行的。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息